S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
NASDAQ:CLRB

Cellectar Biosciences - CLRB News Headlines

$6.25
+0.37 (+6.29%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.77
$6.76
50-Day Range
$3.57
$6.25
52-Week Range
$3.37
$10.90
Volume
96,190 shs
Average Volume
21,534 shs
Market Capitalization
$38.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.25
Get Cellectar Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

CLRB Media Mentions By Week

CLRB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CLRB
News Sentiment

0.44

0.63

Average
Medical
News Sentiment

CLRB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CLRB Articles
This Week

16

1

CLRB Articles
Average Week



SourceHeadline
MarketBeat logoStockNews.com Begins Coverage on Cellectar Biosciences (NASDAQ:CLRB)
americanbankingnews.com - August 12 at 10:54 AM
MarketBeat logoEquities Analysts Set Expectations for Cellectar Biosciences, Inc.'s Q3 2022 Earnings (NASDAQ:CLRB)
americanbankingnews.com - August 12 at 3:24 AM
MarketBeat logoCellectar Biosciences, Inc. Expected to Earn Q1 2023 Earnings of ($0.60) Per Share (NASDAQ:CLRB)
americanbankingnews.com - August 11 at 3:20 AM
MarketBeat logoCellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com
americanbankingnews.com - August 11 at 2:34 AM
baystreet.ca logoCellectar Dips on Q2 Figures
baystreet.ca - August 5 at 9:45 AM
finance.yahoo.com logoCellectar Reports Financial Results for Second Quarter 2022
finance.yahoo.com - August 5 at 9:45 AM
MarketBeat logoCellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com
americanbankingnews.com - August 3 at 2:30 AM
finanznachrichten.de logoCellectar Biosciences: Cellectar Announces Stock Consolidation
finanznachrichten.de - July 22 at 10:36 AM
finance.yahoo.com logoCellectar Announces Stock Consolidation
finance.yahoo.com - July 21 at 7:47 PM
uk.finance.yahoo.com logoCellectar Biosciences, Inc. (CLRB)
uk.finance.yahoo.com - July 19 at 10:24 PM
seekingalpha.com logoCellectar Biosciences GAAP EPS of -$0.10 in-line
seekingalpha.com - May 12 at 7:09 AM
finance.yahoo.com logoCellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update
finance.yahoo.com - May 10 at 12:04 PM
marketwatch.com logoCellectar Biosciences Gets Positive DMC Review for Waldenstrom's Macroglobulinemia Treatment
marketwatch.com - April 26 at 1:22 PM
seekingalpha.com logoCellectar says committee recommends continuing trial of iopofosine in Waldenstrom’s patients
seekingalpha.com - April 26 at 1:22 PM
finance.yahoo.com logoCellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia
finance.yahoo.com - April 26 at 8:22 AM
finance.yahoo.com logoCellectar Biosciences Announces Key Commercial Team Appointments
finance.yahoo.com - April 12 at 9:44 AM
markets.businessinsider.com logoCLRB To Report WM Trial Data In 2H, DICE On Watch, URGN Sees 46%-67% Revenue Growth In 2022
markets.businessinsider.com - March 22 at 5:03 AM
msn.com logoHere's Why Cellectar Biosciences Shares Are Rising
msn.com - March 21 at 7:02 PM
benzinga.com logoRecap: Cellectar Biosciences Q4 Earnings
benzinga.com - March 21 at 9:18 AM
seekingalpha.com logoCellectar Biosciences GAAP EPS of -$0.43 beats by $0.01
seekingalpha.com - March 21 at 9:18 AM
finance.yahoo.com logoCellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update
finance.yahoo.com - March 21 at 9:18 AM
finance.yahoo.com logoCellectar to Participate at Upcoming Banking Conferences
finance.yahoo.com - March 10 at 8:06 PM
seekingalpha.com logoCellectar Biosciences appoints Chad Kolean as CFO, Jarrod Longcor as COO
seekingalpha.com - February 23 at 10:34 AM
finance.yahoo.com logoCellectar Biosciences Announces Executive Leadership Changes
finance.yahoo.com - February 23 at 10:34 AM
finance.yahoo.com logoIs CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - January 17 at 6:06 PM
finance.yahoo.com logoCellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference
finance.yahoo.com - January 5 at 12:24 PM
finance.yahoo.com logoCellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference
finance.yahoo.com - January 4 at 11:18 AM
finance.yahoo.com logoCellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition
finance.yahoo.com - December 13 at 10:20 AM
benzinga.com logoCellectar Biosciences Says Co's Iopofosine I-131 Exhibits Signals Of Efficacy In Phase 1 Study For Pediatric Brain And Solid Tumors
benzinga.com - November 16 at 2:15 PM
finance.yahoo.com logoCellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors
finance.yahoo.com - November 16 at 9:15 AM
proactiveinvestors.com.au logoKazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO
proactiveinvestors.com.au - November 14 at 10:23 PM
finance.yahoo.com logoCellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update
finance.yahoo.com - November 8 at 1:26 PM
finance.yahoo.com logoCellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer
finance.yahoo.com - November 2 at 11:27 AM
finance.yahoo.com logoCellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies
finance.yahoo.com - October 25 at 9:31 AM
finance.yahoo.com logoCellectar Biosciences (NASDAQ:CLRB) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - September 24 at 8:41 AM
finance.yahoo.com logoCellectar Bio's Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer
finance.yahoo.com - September 22 at 7:56 PM
marketwatch.com logoCellectar: Preliminary Iopofosine Data I-131 Suggests Safety, Tolerability in Head and Neck Cancer
marketwatch.com - September 22 at 2:47 PM
finance.yahoo.com logoPreliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer
finance.yahoo.com - September 22 at 9:46 AM
finance.yahoo.com logoCellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
finance.yahoo.com - September 15 at 8:42 PM
finance.yahoo.com logoCellectar Receives $2M NIH Grant For Rare Lymphoma Study
finance.yahoo.com - August 18 at 4:02 PM
finance.yahoo.com logoCellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia
finance.yahoo.com - August 18 at 11:01 AM
finance.yahoo.com logoCellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131
finance.yahoo.com - August 16 at 10:44 AM
finance.yahoo.com logoCellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update
finance.yahoo.com - August 9 at 9:28 AM
finance.yahoo.com logoCellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.
finance.yahoo.com - July 13 at 1:08 PM
finance.yahoo.com logoCellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs)
finance.yahoo.com - July 12 at 1:13 PM
finance.yahoo.com logoCellectar to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
finance.yahoo.com - July 8 at 12:24 PM
finance.yahoo.com logoCellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors
finance.yahoo.com - June 24 at 1:24 PM
finance.yahoo.com logoCellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 4 at 9:28 AM
finance.yahoo.com logoCellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom’s Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 20 at 1:32 PM
finance.yahoo.com logoCellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021
finance.yahoo.com - May 14 at 1:38 PM
Get Cellectar Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:CLRB) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.